National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting, 9410 [E9-4619]
Download as PDF
<![CDATA[
9410
Federal Register / Vol. 74, No. 41 / Wednesday, March 4, 2009 / Notices
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: February 26, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–4616 Filed 3–3–09; 8:45 am]
Dated: February 26, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–4619 Filed 3–3–09; 8:45 am]
BILLING CODE 4140–01–P
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2) notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The purpose of this
meeting is to evaluate requests for
preclinical development resources for
potential new therapeutics for type 1
diabetes. The outcome of the evaluation
will be a decision whether NIDDK
should support the request and make
available contract resources for
development of the potential
therapeutic to improve the treatment or
prevent the development of type 1
diabetes and its complications. The
research proposals and the discussions
could disclose confidential trade secrets
or commercial property such as
patentable material, and personal
information concerning individuals
associated with the proposed research
projects, the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Type 1 Diabetes—
Rapid Access to Intervention Development
VerDate Nov<24>2008
15:08 Mar 03, 2009
Jkt 217001
Special Emphasis Panel; National Institute of
Diabetes and Digestive and Kidney Diseases.
Date: March 27, 2009.
Time: 1 p.m.–3 p.m.
Agenda: To evaluate requests for
preclinical development resources for
potential new therapeutics for type 1 diabetes
and its complications.
Place: 6707 Democracy Boulevard,
Bethesda, MD 20892, (Telephone Conference
Call).
Contact Person: Dr. Myrlelne Staten,
Senior Advisor, Diabetes, Translation
Research, Division of Diabetes,
Endocrinology and Metabolic Diseases,
NIDDK, NIH, 6707 Democracy Boulevard,
Bethesda, MD 20892–5460, 301 402–7886.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 98.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; K-Application SEP.
Date: March 26, 2009.
Time: 12 p.m. to 2 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892, (Telephone
Conference Call).
Contact Person: Xiaodu Guo, MD, PhD,
Scientific Review Officer, Review Branch,
PO 00000
Frm 00029
Fmt 4703
Sfmt 4703
DEA, NIDDK, National Institutes of Health,
Room 761, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, (301) 594–4719,
guox@extra.niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Functional
Dyspepsia and Eradication of H. Pylori-Risks
Vs. Benefits.
Date: April 2, 2009.
Time: 3:30 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892, (Telephone
Conference Call).
Contact Person: Xiaodu Guo, MD, PhD,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 761, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, (301) 594–4719,
guox@extra.niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Lithotripsy Program
Project.
Date: April 7, 2009.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda Marriott Suites, 6711
Democracy Boulevard, Bethesda, MD 20817.
Contact Person: Carol J. Goter-Robinson,
PhD, Scientific Review Officer, Review
Branch, DEA, NIDDK, National Institutes of
Health, Room 748, 6707 Democracy
Boulevard, Bethesda, MD 20892–5452, (301)
594–7791,
goterrobinsonc@extra.niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; AASK Renal Disease
Progression Ancillary Studies.
Date: April 10, 2009.
Time: 1 p.m. to 3 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892, (Telephone
Conference Call).
Contact Person: Robert Wellner, PhD,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 757, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, (301) 594–4721,
rw175w@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: February 26, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–4623 Filed 3–3–09; 8:45 am]
BILLING CODE 4140–01–P
E:\FR\FM\04MRN1.SGM
04MRN1
]]>Agencies
[Federal Register Volume 74, Number 41 (Wednesday, March 4, 2009)]
[Notices]
[Page 9410]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-4619]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases;
Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2) notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The purpose of this meeting is to evaluate requests
for preclinical development resources for potential new therapeutics
for type 1 diabetes. The outcome of the evaluation will be a decision
whether NIDDK should support the request and make available contract
resources for development of the potential therapeutic to improve the
treatment or prevent the development of type 1 diabetes and its
complications. The research proposals and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the proposed research projects, the disclosure of which
would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Type 1 Diabetes--Rapid Access to Intervention
Development Special Emphasis Panel; National Institute of Diabetes
and Digestive and Kidney Diseases.
Date: March 27, 2009.
Time: 1 p.m.-3 p.m.
Agenda: To evaluate requests for preclinical development
resources for potential new therapeutics for type 1 diabetes and its
complications.
Place: 6707 Democracy Boulevard, Bethesda, MD 20892, (Telephone
Conference Call).
Contact Person: Dr. Myrlelne Staten, Senior Advisor, Diabetes,
Translation Research, Division of Diabetes, Endocrinology and
Metabolic Diseases, NIDDK, NIH, 6707 Democracy Boulevard, Bethesda,
MD 20892-5460, 301 402-7886.
(Catalogue of Federal Domestic Assistance Program Nos. 93.847,
Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive
Diseases and Nutrition Research; 98.849, Kidney Diseases, Urology
and Hematology Research, National Institutes of Health, HHS)
Dated: February 26, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. E9-4619 Filed 3-3-09; 8:45 am]
BILLING CODE 4140-01-P
